(Circulation. 2000;102:945.)
© 2000 American Heart Association, Inc.
Brief Rapid Communications |
The Elusive Link Between LQT3 and Brugada Syndrome
The Role of Flecainide Challenge
From the Department of Molecular Cardiology (S.G.P., C.N., E.R.), Fondazione Salvatore Maugeri, IRCCS, Pavia, Italy, and the Department of Cardiology (S.G.P., C.N., P.J.S., R.B., L.C.), University of Pavia and Policlinico S. Matteo, Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Italy.
Correspondence to Silvia G. Priori, MD, PhD, Director of Molecular Cardiology, Fondazione Salvatore Maugeri, Via Ferrata 8, 27100 Pavia, Italy. E-mail spriori{at}fsm.it
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Defects of the SCN5A gene encoding the cardiac sodium channel are associated with both the LQT3 subtype of long-QT syndrome and Brugada syndrome (BS). The typical manifestations of long-QT syndrome (QT interval prolongation) and BS (ST segment elevation in leads V1 through V3) may coexist in the same patients, which raises questions about the actual differences between LQT3 and BS. Intravenous flecainide is the standard provocative test used to unmask BS in individuals with concealed forms of the disease, and oral flecainide has been proposed as a treatment option for LQT3 patients because it may shorten their QT interval.
Methods and Results—We tested the possibility that in some LQT3
patients, flecainide might not only shorten the QT interval, but also
produce an elevation of the ST segment. A total of 13 patients from 7
LQT3 families received intravenous flecainide using the
protocol used for BS. As expected, QT, QTc, JT, and JTc interval
shortening was observed in 12 of the 13 patients, and concomitant ST
segment elevation in leads V1 through V3 (
2 mm) was observed in
6 of the 13.
Conclusions—The data demonstrate that flecainide may induce ST segment elevation in LQT3 patients, raising concerns about the safety of flecainide therapy and demonstrating the existence of an intriguing overlap between LQT3 and BS.
Key Words: long-QT syndrome • Brugada syndrome • arrhythmia • drugs
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Mutations of the cardiac sodium channel gene, SCN5A, are present both in the long-QT syndrome LQT3 subtype1 and in Brugada Syndrome (BS).2 One mutation resulting in a phenotype combining QT prolongation and ST segment elevation has been reported,3 suggesting that the distinction between LQT3 and BS may be more blurred than currently recognized.
Intravenous flecainide, a sodium channel blocker, is widely used as a provocative test to unmask the ECG phenotype of BS and, as such, is regarded as highly specific for the disease.4 Oral flecainide has shortened the QT interval in a few LQT3 patients,5 leading to the suggestion of using it as a specific long-term treatment for LQT3. If these seemingly differential responses of LQT3 and BS patients to flecainide are indeed specific, then this drug might represent a tool to better distinguish the 2 diseases.
In 13 LQT3 patients who carry 7 different mutations, we evaluated the response to intravenous flecainide and found that flecainide elicited the ECG pattern typical for BS in 6 of the 13. This finding raises concerns about the safety of flecainide therapy in long-QT syndrome patients and demonstrates the existence of an intriguing overlap between the 2 diseases.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Clinical Evaluation
The 13 consecutively genotyped LQT3 patients included in the present study underwent a complete, noninvasive cardiac evaluation at our clinical center. Physical examination, ECG, exercise stress test, and 12-lead Holter recording were performed. Long-QT syndrome was diagnosed based on standard criteria.6
Flecainide was administered intravenously at a dose of 2 mg/kg over 10 minutes. A standard 12-lead ECG was continuously monitored during the test and for the following 30 minutes.
Molecular Screening
Genomic DNA was extracted from peripheral blood
lymphocytes by standard techniques. The region of SCN5A
encoding the cardiac sodium channel 
-subunit was screened using
single-strand conformation polymorphism on polymerase chain
reaction–amplified genomic DNA samples. The abnormal conformers were
directly sequenced using an ABI310 genetic analyzer or were
cloned (TopoTA cloning, Invitrogen) and sequenced using
plasmid-specific oligonucleotides. Shifts in
single-strand conformation polymorphism were also checked against a
panel of genomic DNA from 300 healthy reference individuals (600
chromosomes). In all patients, the presence of a second mutation in the
remaining long-QT syndrome–related genes was excluded by molecular
analysis.
Statistical Analysis
Data are expressed as mean±SD. Statistical analysis was
performed using the SPSS statistical package. A paired t
test was used for the evaluation of changes in ECG
parameters before and after flecainide; significance was
accepted for P<0.05. Linear regression analysis was
used to assess the correlation between variables.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The mean age of the 13 LQT3 patients (7 men) was 37±18 years. Seven were symptomatic for repeated syncope, and 2 had been hospitalized for incessant runs of torsade de pointes. The QT interval was prolonged in 12 of the 13 patients (mean QT, 501±45 ms; mean QTc, 504±39 ms), and one had right bundle branch block. The patient with a normal QT interval was referred to our attention for the evaluation of presyncopal events. Mutations identified in SCN5A were
KPQ 1505 to 1507 (n=1), E1784K (n=3), V411M
(n=1), K1500 (n=5), R1626P (n=1), T1304M (n=1), and P2006A
(n=1).
Flecainide administration significantly prolonged the PQ interval (from
164±23 to 186±22 ms; P<0.001), widened the QRS interval
(from 104±25 to 126±24 ms; P<0.001), and shortened the QT
(from 502±45 to 460±30 ms; P<0.0001), QTc (from 504±39
to 473±28 ms; P<0.01), JT (from 397±54 to 334±34 ms;
P<0.001) and JTc intervals (from 399±51 to 347±29 ms;
P<0.001; Figure 1
). The RR
interval was slightly but consistently reduced in all patients
(from 981 to 931 ms; P<0.05). The mean percent reduction of
JTc (JTc%) was 12.4%
(range, 2% to 20%). The patient with no change in
JTc% was the patient
with a normal QT interval at baseline. Only a modest correlation was
present between JTc at baseline and the
JTc% reduction after
flecainide (r2=0.58). No correlation was observed
between JTc% and RR
shortening (r2=0.036) or between
JTc% and QRS widening
(r2=0.034).
|
ST segment elevation in leads V1 through V3 (2 mm) after
flecainide occurred in 6 of the 13 patients; these 6 patients had trend
toward a shorter baseline QTc and JTc compared with patients without ST
segment elevation (JTc, 372±26 versus 424±56; P=0.006). No
difference in the shortening of QT, QTc, JT, JTc, or
JTc% after flecainide
was observed between the patients with (n=6) and without (n=7) ST
segment elevation. ST segment elevation occurred in a similar
percentage of symptomatic and asymptomatic
patients.
Two of the 7 mutations (KPQ 1505 to 1507, E1784K) have been
expressed in heterologous systems and are associated with the delayed
fast inactivation of the sodium current.7 8 The
development of ST segment elevation seemed unrelated to the specific
mutations and to their electrophysiological
effects. Not all patients with the same genetic defect had a concordant
response to the flecainide test. Specifically, in a family with 3
carriers of the E1784K defect (baseline QTc of 496, 510, and 520 ms),
QT shortening was observed in all patients, but only one developed
marked ST segment elevation (Figure 2).
|
The patient with a normal QTc interval at baseline (Figure 1
) is
a carrier of the T1304M mutation that has been described in association
with the LQT3 phenotype9 ; he did not develop ST
segment elevation after flecainide.
In one patient with a familial form of LQT3 in whom flecainide induced QT shortening and ST segment elevation, an analysis of ECGs recorded 30 years earlier revealed that twice he presented with spontaneous ST segment elevation.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This study provides evidence that intravenous flecainide at the dose used to unmask concealed BS4 may induce ST segment elevation and QT shortening in LQT3 patients. The appearance of the ECG pattern that, according to current standards, is diagnostic for BS raises concerns about placing LQT3 patients on long-term treatment with flecainide.
Ajmaline and flecainide administration was proposed by Brugada et al4 as a diagnostic test for the identification of concealed forms of BS. Accordingly, individuals with mild ST segment elevation and their family members are exposed to this provocative test and diagnosed as "affected" by BS whenever a 1-mm ST segment elevation occurs.4 We recently questioned the sensitivity of the flecainide test when we identified family members of BS probands who carried the genetic defect but failed to manifest ST segment elevation during pharmacological challenge (unpublished data). Data reported here show that flecainide administration may also induce ST segment elevation in leads V1 through V3 in LQT3 patients.
The rationale for using sodium channel blockers in LQT3 is based on the
experimental evidence that mexiletine reduces the action potential
prolongation produced by delayed inactivation of the sodium
current10 and the persistent inward current associated
with 3 mutations (KPQ, R1644H, and N1325S).7 Indeed,
acute oral testing with mexiletine shortened the QT interval in LQT3
patients.11
Recently, Benhorin et al5 reported that oral flecainide significantly shortened the QT interval in 8 asymptomatic members of one LQT3 family; intravenous administration of the drug was not done, and patients were placed on long-term treatment, with persistence of the QT interval shortening over time. Benhorin et al5 conclude by saying that the response to flecainide could be either gene-specific or mutation-specific. In fact, the picture could be even more complex: our data raise the possibility that it may be "individual specific." In one family, all 3 affected members with marked QT interval prolongation had QT shortening with flecainide; however, the one with the more modest shortening (32 ms versus 58 and 64 ms) also developed ST segment elevation. Like the puzzling issue of incomplete penetrance, with some family members carrying the mutation but not manifesting QT prolongation,12 13 it may also be true that the response to sodium channel blockade shows individual variability or that it lacks reproducibility within the same patient. This raises uncertainties about the negative predictive value of the lack of ST segment elevation after the intravenous administration of flecainide and questions the overall safety of long-term treatment with flecainide in LQT3.
These findings prompt 2 considerations relevant to clinical practice. (1) The similar response of LQT3 and BS patients to flecainide challenge, combined with the common clinical features of the 2 diseases (suspected or certain lack of therapeutic efficacy of ß-blockers,14 high lethality of cardiac events,14 and arrhythmias occurring at rest or sleep15 ), demonstrates that the phenotypic overlapping of LQT3 and BS is larger than commonly appreciated. (2) The evidence that flecainide may provoke ST segment elevation calls for caution in initiating long-term flecainide treatment in LQT3 patients.
|
Acknowledgments |
|---|
We wish to acknowledge the contribution of Telethon grant 1058.
Received May 2, 2000; revision received July 5, 2000; accepted July 12, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80:805–811.[Medline] [Order article via Infotrieve]
2. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998;392:293–296.[Medline] [Order article via Infotrieve]
3.
Bezzina C, Veldkamp MW, van Den Berg MP, et al. A
single Na(+) channel mutation causing both long-QT and Brugada
syndromes. Circ Res. 1999;85:1206–1213.
4.
Brugada R, Brugada J, Antzelevitch C, et al. Sodium
channel blockers identify risk for sudden death in patients with
ST-segment elevation and right bundle branch block but structurally
normal hearts. Circulation. 2000;101:510–515.
5.
Benhorin J, Taub R, Goldmit M, et al. Effects of
flecainide in patients with new SCN5A mutation: mutation-specific
therapy for long QT syndrome? Circulation.. 2000;101:1698–1706.
6.
Schwartz PJ, Moss AJ, Vincent GM, et al.
Diagnostic criteria for the long QT syndrome: an update.
Circulation. 1993;88:782–784.
7.
Dumaine R, Wang Q, Keating MT, et al. Multiple
mechanisms of Na+ channel-linked long-QT syndrome Circ Res. 1996;78:916–924.
8.
Wei J, Wang DW, Alings M, et al. Congenital long-QT
syndrome caused by a novel mutation in a conserved acidic domain of the
cardiac Na+ channel. Circulation. 1999;99:3165–3171.
9. Wattanasirichaigoon D, Vesely MR, Duggal P, et al. Sodium channel abnormalities are infrequent in patients with long QT syndrome: identification of two novel SCN5A mutations. Am J Med Genet. 1999;86:470–476.
10.
Priori SG, Napolitano C, Cantù F, et al.
Differential response to Na+ channel blockade, ß-adrenergic
stimulation, and rapid pacing in a cellular model mimicking the SCN5A
and HERG defects present in the long-QT syndrome. Circ
Res. 1996;78:1009–1015.
11.
Schwartz PJ, Priori SG, Locati EH, et al. Long QT
syndrome patients with mutations of the SCN5A and HERG genes have
differential responses to Na+ channel blockade and to increases in
heart rate: implications for gene-specific therapy.
Circulation. 1995;92:3381–3386.
12. Vincent GM, Timothy KM, Leppert M, et al. The spectrum of symptoms and QT intervals in carriers of the gene for long QT syndrome. N Engl J Med. 1992;327:846–852.[Abstract]
13.
Priori SG, Napolitano C, Schwartz PJ. Low penetrance in
the long QT syndrome: clinical impact. Circulation. 1999;99:529–533.
14.
Zareba W, Moss AJ, Schwartz PJ, et al. Influence
of the genotype on the clinical course of the long QT syndrome.
N Engl J Med. 1998;339:960–965.
15. Schwartz PJ, Priori SG, Napolitano C. Long QT syndrome. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 3rd ed. Philadelphia: Saunders; 2000:597–615.
This article has been cited by other articles:
 |
|
 |
|
  R. Shephard and C. Semsarian Advances in the prevention of sudden cardiac death in the young Therapeutic Advances in Cardiovascular Disease, April 1, 2009; 3(2): 145 - 155. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Petitprez, T. Jespersen, E. Pruvot, D. I. Keller, C. Corbaz, J. Schlapfer, H. Abriel, and J. P. Kucera Analyses of a novel SCN5A mutation (C1850S): conduction vs. repolarization disorder hypotheses in the Brugada syndrome Cardiovasc Res, June 1, 2008; 78(3): 494 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nagase, K. F. Kusano, H. Morita, N. Nishii, K. Banba, A. Watanabe, S. Hiramatsu, K. Nakamura, S. Sakuragi, and T. Ohe Longer Repolarization in the Epicardium at the Right Ventricular Outflow Tract Causes Type 1 Electrocardiogram in Patients With Brugada Syndrome J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1154 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Roden Long-QT Syndrome N. Engl. J. Med., January 10, 2008; 358(2): 169 - 176. [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Shang, A. E. Pfahnl, S. Sanyal, Z. Jiao, J. Allen, K. Banach, J. Fahrenbach, D. Weiss, W. R. Taylor, A. M. Zafari, et al. Human Heart Failure Is Associated With Abnormal C-Terminal Splicing Variants in the Cardiac Sodium Channel Circ. Res., November 26, 2007; 101(11): 1146 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Stephenson and C. I. Berul Electrophysiological Interventions for Inherited Arrhythmia Syndromes Circulation, August 28, 2007; 116(9): 1062 - 1080. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Frigo, A. Rampazzo, B. Bauce, K. Pilichou, G. Beffagna, G. A. Danieli, A. Nava, and B. Martini Homozygous SCN5A mutation in Brugada syndrome with monomorphic ventricular tachycardia and structural heart abnormalities Europace, June 1, 2007; 9(6): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Stokoe, R. Balasubramaniam, C. A. Goddard, W. H. Colledge, A. A. Grace, and C. L.-H. Huang Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/ murine hearts modelling the Brugada syndrome J. Physiol., May 15, 2007; 581(1): 255 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Arnestad, L. Crotti, T. O. Rognum, R. Insolia, M. Pedrazzini, C. Ferrandi, A. Vege, D. W. Wang, T. E. Rhodes, A. L. George Jr, et al. Prevalence of Long-QT Syndrome Gene Variants in Sudden Infant Death Syndrome Circulation, January 23, 2007; 115(3): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Stokoe, G. Thomas, C. A. Goddard, W. H. Colledge, A. A. Grace, and C. L.-H. Huang Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/{Delta} murine hearts modelling long QT syndrome 3 J. Physiol., January 1, 2007; 578(1): 69 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Remme, A. O. Verkerk, D. Nuyens, A. C. G. van Ginneken, S. van Brunschot, C. N. W. Belterman, R. Wilders, M. A. van Roon, H. L. Tan, A. A. M. Wilde, et al. Overlap Syndrome of Cardiac Sodium Channel Disease in Mice Carrying the Equivalent Mutation of Human SCN5A-1795insD Circulation, December 12, 2006; 114(24): 2584 - 2594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Schulze-Bahr Arrhythmia Predisposition: Between Rare Disease Paradigms and Common Ion Channel Gene Variants J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A67 - A78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Shimizu The long QT syndrome: Therapeutic implications of a genetic diagnosis Cardiovasc Res, August 15, 2005; 67(3): 347 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C.M. Beaufort-Krol, M. P. van den Berg, A. A.M. Wilde, J. P. van Tintelen, J. W. Viersma, C. R. Bezzina, and M. Th.E. Bink-Boelkens Developmental Aspects of Long QT Syndrome Type 3 and Brugada Syndrome on the Basis of a Single SCN5A Mutation in Childhood J. Am. Coll. Cardiol., July 19, 2005; 46(2): 331 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Brugada, R. Brugada, J. Brugada, S. G. Priori, C. Napolitano, P. Brugada, R. Brugada, J. Brugada, S. G. Priori, and C. Napolitano Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation, July 12, 2005; 112(2): 279 - 292. [Full Text] [PDF]
|
|
|
|
|
|
A. D.J. Ten Harkel, M. Witsenburg, P. L. de Jong, L. Jordaens, M. Wijman, and A. A.M. Wilde Efficacy of an implantable cardioverter-defibrillator in a neonate with LQT3 associated arrhythmias Europace, January 1, 2005; 7(1): 77 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. D. Wever and E. O. Robles de Medina Sudden death in patients without structural heart disease J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1137 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Morita, S. T. Morita, S. Nagase, K. Banba, N. Nishii, Y. Tani, A. Watanabe, K. Nakamura, K. F. Kusano, T. Emori, et al. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1624 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nademanee, G. Veerakul, M. Mower, K. Likittanasombat, R. Krittayapong, K. Bhuripanyo, S. Sitthisook, L. Chaothawee, M. Y. Lai, and S. P. Azen Defibrillator Versus {beta}-Blockers for Unexplained Death in Thailand (DEBUT): A Randomized Clinical Trial Circulation, May 6, 2003; 107(17): 2221 - 2226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L Tan, C. R Bezzina, J. P.P Smits, A. O Verkerk, and A. A.M Wilde Genetic control of sodium channel function Cardiovasc Res, March 15, 2003; 57(4): 961 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Booker, S. D. Whyte, and E. J. Ladusans Long QT syndrome and anaesthesia Br. J. Anaesth., March 1, 2003; 90(3): 349 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Takagi, N Aihara, S Kuribayashi, A Taguchi, T Kurita, K Suyama, S Kamakura, and M Takamiya Abnormal response to sodium channel blockers in patients with Brugada syndrome: augmented localised wall motion abnormalities in the right ventricular outflow tract region detected by electron beam computed tomography Heart, February 1, 2003; 89(2): 169 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Moric, E. Herbert, M. Trusz-Gluza, A. Filipecki, U. Mazurek, and T. Wilczok The implications of genetic mutations in the sodium channel gene (SCN5A) Europace, January 1, 2003; 5(4): 325 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. H.T. Wehrens, M. A. Vos, P. A. Doevendans, and H. J.J. Wellens Novel Insights in the Congenital Long QT Syndrome Ann Intern Med, December 17, 2002; 137(12): 981 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A.M. Wilde, C. Antzelevitch, M. Borggrefe, J. Brugada, R. Brugada, P. Brugada, D. Corrado, R. N.W. Hauer, R. S. Kass, K. Nademanee, et al. Proposed Diagnostic Criteria for the Brugada Syndrome: Consensus Report Circulation, November 5, 2002; 106(19): 2514 - 2519. [Full Text] [PDF]
|
|
|
|
 |
|
 A.A.M. Wilde, C. Antzelevitch, M. Borggrefe, J. Brugada, R. Brugada, P. Brugada, D. Corrado, R.N.W. Hauer, R.S. Kass, K. Nademanee, et al. Proposed Diagnostic Criteria for the Brugada Syndrome Eur. Heart J., November 1, 2002; 23(21): 1648 - 1654. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Bauman and R. J. DiDomenico Cocaine-Induced Channelopathies: Emerging Evidence on the Multiple Mechanisms of Sudden Death Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2002; 7(3): 195 - 202. [Abstract] [PDF]
|
|
|
|
|
|
C. R Bezzina and H. L Tan Pharmacological rescue of mutant ion channels Cardiovasc Res, August 1, 2002; 55(2): 229 - 232. [Full Text] [PDF]
|
|
|
|
|
|
T. Kurita, W. Shimizu, M. Inagaki, K. Suyama, A. Taguchi, K. Satomi, N. Aihara, S. Kamakura, J. Kobayashi, and Y. Kosakai The electrophysiologic mechanism of ST-segment elevation in Brugada syndrome J. Am. Coll. Cardiol., July 17, 2002; 40(2): 330 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Liu, M. Tateyama, C. E. Clancy, H. Abriel, and R. S. Kass Channel Openings Are Necessary but not Sufficient for Use-dependent Block of Cardiac Na+ Channels by Flecainide: Evidence from the Analysis of Disease-linked Mutations J. Gen. Physiol., June 24, 2002; 120(1): 39 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Balser Inherited sodium channelopathies: models for acquired arrhythmias? Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1175 - H1180. [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Bruns, L. Eckardt, C. Vahlhaus, E. Schulze-Bahr, W. Haverkamp, M. Borggrefe, G. Breithardt, and T. Wichter Body surface potential mapping in patients with Brugada syndrome: right precordial ST segment variations and reverse changes in left precordial leads Cardiovasc Res, April 1, 2002; 54(1): 58 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shirai, N. Makita, K. Sasaki, H. Yokoi, I. Sakuma, H. Sakurada, J. Akai, A. Kimura, M. Hiraoka, and A. Kitabatake A mutant cardiac sodium channel with multiple biophysical defects associated with overlapping clinical features of Brugada syndrome and cardiac conduction disease Cardiovasc Res, February 1, 2002; 53(2): 348 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kyndt, V. Probst, F. Potet, S. Demolombe, J.-C. Chevallier, I. Baro, J.-P. Moisan, P. Boisseau, J.-J. Schott, D. Escande, et al. Novel SCN5A Mutation Leading Either to Isolated Cardiac Conduction Defect or Brugada Syndrome in a Large French Family Circulation, December 18, 2001; 104(25): 3081 - 3086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Viswanathan, C. R. Bezzina, A. L. George Jr., D. M. Roden, A. A.M. Wilde, and J. R. Balser Gating-Dependent Mechanisms for Flecainide Action in SCN5A-Linked Arrhythmia Syndromes Circulation, September 4, 2001; 104(10): 1200 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Rivolta, H. Abriel, M. Tateyama, H. Liu, M. Memmi, P. Vardas, C. Napolitano, S. G. Priori, and R. S. Kass Inherited Brugada and Long QT-3 Syndrome Mutations of a Single Residue of the Cardiac Sodium Channel Confer Distinct Channel and Clinical Phenotypes J. Biol. Chem., August 10, 2001; 276(33): 30623 - 30630. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||